Marengo Asia Hospitals, the eight-hospital chain backed by Samara Capital and the family offices of the Godrej Group and Havells India promoters, is looking to sell a 10% stake to external investors for ₹500 crore — a transaction that would peg its valuation at approximately ₹5,000 crore. An information memorandum has already been circulated to a shortlist of sovereign wealth funds, pension funds, and specialised healthcare investors, according to people familiar with the matter. Investment bank Avendus Capital has been engaged to facilitate the process.
A Founder-Funded Network Now Seeking Its First External Price Discovery
What makes this fundraise structurally distinctive is its stated intent. The founding investors are not raising capital out of financial distress or to fund an immediate acquisition spree — they are seeking, in the language of private markets, a valuation benchmark. Since the company's inception, Samara Capital and the two family offices have funded Marengo Asia entirely from their own balance sheets. Bringing in an external institutional investor at a defined price sets a reference point for future rounds, potential public listings, or secondary transactions.
This approach is increasingly common among founder-backed or PE-backed healthcare platforms in India that have reached a scale requiring credible third-party validation of enterprise value. A sovereign wealth fund or pension fund investing at ₹5,000 crore implies a level of institutional rigour — due diligence, independent financial analysis, governance standards — that internal funding rounds do not demand. The stake sale, if completed, effectively transforms the company's capital structure from a closely held co-investment into one with a publicly acknowledged market price.
Built Through Aggregation: The Architecture of the Marengo Network
Marengo Asia's founding agreement, struck in October 2020, was unusual in Indian healthcare. Rather than building hospitals from the ground up — a capital-intensive and slow process — the consortium opted for an aggregation model: identifying existing hospitals with established patient bases, bringing them into a unified brand and operational framework, and using that base to pursue further acquisitions.
The first asset brought into the network was QRG Hospital in Faridabad, NCR — renamed in honour of Qimat Rai Gupta, the founder of Havells India, and already an established facility in the region. CIMS Hospital in Ahmedabad followed, giving the network a meaningful foothold in Gujarat. Subsequent bolt-on acquisitions extended the geographic reach: Sunshine Global Hospitals, with facilities in Surat and Vadodara, was acquired last year. W Pratiksha Hospital in Gurugram added another NCR asset. A strategic tie-up with Varanasi-based Metis-Medicity extended the network into Uttar Pradesh. The company now operates across NCR, Gujarat, Rajasthan, and, notably, Saudi Arabia — a market that relatively few Indian hospital chains have entered directly.
Marengo Asia's founder, Raajiv Singhal, brings an operational background that spans military medicine and several of India's largest private hospital groups, including Fortis Healthcare, Aditya Birla Group, Sakra Hospital, and Care Hospitals. That range of experience is relevant context for a company that has had to integrate hospitals with different operational cultures, billing systems, and clinical standards under a single brand.
Revenue Scale and What It Signals for the Sector
The company reported revenue of ₹1,200 crore in the financial year 2025-26, across a network of 2,500 beds. That translates to a revenue-per-bed figure that reflects the mid-tier to upper-mid-tier positioning typical of well-run multi-city hospital chains in India. The implied valuation of ₹5,000 crore — roughly 4.2 times revenue — sits within the range that listed Indian hospital companies have commanded in recent years, though precise comparisons depend on EBITDA margins and debt levels that have not been disclosed publicly.
The broader context is a healthcare sector that has attracted sustained institutional interest. India's hospital industry has seen a wave of consolidation over the past several years, as organised chains with professional management and standardised care protocols have absorbed smaller single-city operators. Marengo Asia's aggregation strategy sits within this broader trend. What distinguishes it is the identity of its backers — a combination of a private equity firm and two of India's most prominent industrial family offices — and the deliberate pace of its expansion, which has prioritised asset quality and geographic diversity over rapid bed count growth.
With funds already earmarked for acquisitions in Rajasthan and Maharashtra, the company is evidently not finished building. A successful stake sale at the targeted valuation would provide both a capital infusion and the institutional credibility that tends to precede either a larger fundraise or a public market listing.
